Nascent Biotech, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 2.8 million compared to USD 0.47039 million a year ago. Basic loss per share from continuing operations was USD 0.02.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0889 USD | 0.00% | -1.11% | -48.58% |
1st Jan change | Capi. | |
---|---|---|
-48.58% | 15.17M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- NBIO Stock
- News Nascent Biotech, Inc.
- Nascent Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023